Enveda , a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Management, with participation from Iconiq and others, doubles the valuation Enveda achieved 12 months ago. The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharm…
Why this update matters
This developing story is relevant for readers tracking technology because it reflects fresh changes from the original source and signals where attention is shifting next.
Key details
The report was collected automatically and prepared for publication with a newsroom workflow that focuses on clarity, search visibility, and quick understanding.
Readers should review the original source for direct statements, official notices, and any later corrections or additions as the story evolves.
Related coverage
Continue reading with more reporting from the same topic cluster.